Clinical Trials & Medical Devices Masterclass
This masterclass provides comprehensive coverage of clinical trials and medical device regulations for the UPSC Drug Inspector 2026 exam. It synthesizes high-yield information from the ND&CT Rules 2019, Medical Devices Rules 2017, and ICH-GCP guidelines, emphasizing critical phases, regulatory processes, ethics, and key statistical concepts, alongside vital PYQ-based insights and quick revision tables for optimal preparation.
SECTION A: CLINICAL TRIALS - COMPLETE COVERAGE
1. CLINICAL TRIAL PHASES (HIGH-YIELD | Asked in 2018, 2019, 2023)
PHASE I (First-in-Human / Human Pharmacology)
- Subjects: 20-100 HEALTHY VOLUNTEERS (except oncology/critical diseases)
- Purpose: Safety, tolerability, PK (pharmacokinetics), PD (pharmacodynamics)
- Key: Dose escalation study, Maximum Tolerated Dose (MTD)
- Sub-types:
- Single Ascending Dose (SAD)
- Multiple Ascending Dose (MAD)
- Food effect studies
- Drug-drug interaction studies
PHASE II (Therapeutic Exploratory / Proof of Concept)
- Subjects: 100-300 PATIENTS with target disease
- Purpose: Efficacy proof, dose-finding, optimal dosing regimen
- Sub-types:
- Phase IIa: Pilot efficacy studies
- Phase IIb: Dose-response studies (definitive dose finding)
- Key: First evidence of therapeutic effect
PHASE III (Therapeutic Confirmatory / Pivotal Trials)
- Subjects: 1000-3000+ patients, MULTICENTRIC, RANDOMIZED CONTROLLED
- Purpose: Confirm efficacy & safety in larger population
- Key: Pivotal for regulatory approval, compared with standard of care/placebo
- Types: Superiority, Non-inferiority, Equivalence trials
PHASE IV (Post-Marketing Surveillance / Pharmacovigilance)
- Subjects: Large population (thousands to millions)
- Purpose: Rare ADRs, long-term safety, new indications, cost-effectiveness
- Methods: Observational studies, cohort studies, case-control studies
- Key: Detects ADRs with incidence <1/10,000 (too rare for Phase III)
PYQ TIP: Questions often ask: "Which phase uses healthy volunteers?" → Phase I
"Which phase detects rare ADRs?" → Phase IV
"Minimum subjects for Phase III?" → 1000+
2. NEW DRUGS & CLINICAL TRIALS RULES, 2019 (ND&CT RULES 2019) (CRITICAL | DIRECTLY TESTED IN 2023 PYQ)
DEFINITION OF "NEW DRUG" (Rule 2(1)(w)):
A drug that has NOT been used in India to any significant extent under the conditions prescribed, recommended, or suggested in the labelling thereof, AND has NOT been recognized as effective and safe by the Central Licensing Authority.
Also includes:
- Drug approved by CLA for certain claims but now proposed for NEW CLAIMS
- Fixed Dose Combination (FDC) not previously approved
- New dosage form / new route of administration
- New strength / new indication
- Modified release formulation of existing drug
- Vaccine, recombinant product, biosimilar
- All biological products unless specifically exempted
WAIVER OF PHASE I (Important PYQ topic):
- Phase I may be WAIVED if drug is ALREADY APPROVED in ICH countries (USA, EU, Japan, Canada, Switzerland, Australia)
- Requires: Complete Phase I data from that country + Ethics Committee approval
- DCGI (Drugs Controller General of India) has final authority
ETHICS COMMITTEE (EC) REQUIREMENTS:
- Must be REGISTERED with DCGI (mandatory)
- Composition (as per Schedule Y):
- Chairperson (independent, not from same institution)
- 1-2 basic medical scientists
- 1-2 clinicians from different specialties
- 1 legal expert
- 1 social scientist/representative of NGO
- 1 philosopher/ethicist/theologian
- 1 lay person from community
- Member Secretary
- At least ONE independent member not affiliated with institution
- Functions: Review trial protocols, monitor ongoing trials, review SAEs
- Meeting: Quorum = minimum 5 members including Chairperson + 1 clinician
INFORMED CONSENT - 11 ESSENTIAL ELEMENTS (Schedule Y / ND&CT Rules):
- Statement that study involves research + explanation of purpose
- Expected duration of subject's participation
- Description of procedures to be followed
- Description of foreseeable risks/discomforts
- Description of benefits to subject/others
- Disclosure of alternative procedures/treatments
- Statement describing extent of confidentiality
- Compensation and treatment for research-related injury
- Contact person for questions about research and subject's rights
- Statement that participation is voluntary + no penalty for withdrawal
- Circumstances under which subject's participation may be terminated
PYQ TIP: Questions on "Compensation for trial-related injury" → MUST be mentioned
"Can subject withdraw anytime?" → YES, without penalty
SERIOUS ADVERSE EVENT (SAE) REPORTING TIMELINES:
- FATAL / LIFE-THREATENING SAE: Report within 7 DAYS to EC + DCGI
- OTHER SERIOUS SAEs: Report within 15 DAYS
- SUSAR (Suspected Unexpected Serious Adverse Reaction): Same timelines
- Follow-up reports must be submitted as information becomes available
CRITICAL: Sponsor MUST provide FREE MEDICAL MANAGEMENT + COMPENSATION for trial-related injury or death (Rule 81 of ND&CT Rules 2019)
INVESTIGATIONAL NEW DRUG (IND) APPLICATION:
- Required BEFORE starting clinical trials in India
- Submitted to DCGI office
- Contains: Chemistry/Manufacturing/Controls (CMC), Preclinical data, Clinical protocol, Investigator brochure, Informed consent form
- DCGI review period: 30 working days (silent approval if no response)
NEW DRUG APPLICATION (NDA) / MARKETING AUTHORIZATION:
- Submitted after successful Phase III
- Format: CTD (Common Technical Document) - ICH M4 format
- Modules:
- Module 1: Administrative & prescribing information (region-specific)
- Module 2: Common Technical Document Summaries (Quality, Safety, Efficacy)
- Module 3: Quality (CMC data)
- Module 4: Non-clinical study reports
- Module 5: Clinical study reports
- DCGI approval required before marketing in India
3. STUDY DESIGNS & METHODOLOGY (Frequently Tested)
RANDOMIZATION METHODS:
- Simple Randomization: Coin toss, random number tables, computer-generated
- Block Randomization: Ensures equal group sizes in blocks (e.g., block of 4)
- Stratified Randomization: Randomization within subgroups (age, sex, severity)
- Cluster Randomization: Randomizes groups/communities (not individuals)
BLINDING:
- Open-label: No blinding (both know treatment)
- Single-blind: Only patient blinded
- Double-blind: Both patient AND investigator blinded (GOLD STANDARD)
- Triple-blind: Patient, investigator, AND data analyst blinded
STUDY DESIGN TYPES:
- Parallel Design: Two+ groups receive different treatments simultaneously
- Crossover Design: Subjects receive treatments in sequence with washout period
- Advantage: Reduced inter-subject variability
- Disadvantage: Carryover effects, longer duration
- Factorial Design: Multiple treatments evaluated simultaneously
- Example: 2×2 factorial = 4 treatment combinations
- Adaptive Design: Pre-planned modifications based on interim data
- Types: Adaptive randomization, sample size re-estimation, seamless Phase II/III
CONSORT GUIDELINES:
- CONsolidated Standards Of Reporting Trials
- Mandatory for publication in major journals
- Includes: Flow diagram + 25-item checklist
- Ensures transparency in reporting RCTs
4. GOOD CLINICAL PRACTICE (GCP) - ICH E6 (R2) (Rising topic | 2019 & 2023 PYQ)
5 KEY PRINCIPLES OF GCP:
- ETHICAL CONDUCT: Trials should be conducted in accordance with ethical principles originating in Declaration of Helsinki
- SCIENTIFIC QUALITY: Should be scientifically sound and described in clear protocol
- RISK-BENEFIT BALANCE: Foreseeable risks should be weighed against anticipated benefits
- INFORMED CONSENT: Freely given informed consent from every subject
- CONFIDENTIALITY: Privacy and confidentiality of records maintained
ROLES & RESPONSIBILITIES:
SPONSOR:
- Initiates, manages, and/or finances clinical trial
- Responsible for trial design, protocol development, investigator selection
- Must provide insurance/indemnity for trial subjects
- Quality assurance and quality control
- SAE reporting to regulatory authorities
INVESTIGATOR:
- Qualified physician/dentist responsible for conduct at trial site
- Personally conducts or supervises the trial
- Responsible for medical care of trial subjects
- Maintains accurate source documents and CRFs
- Must have adequate resources (staff, facilities, time)
MONITOR (CRA - Clinical Research Associate):
- Represents sponsor at trial site
- Verifies CRF data against source documents
- Ensures protocol compliance
- Checks informed consent documentation
- Reports to sponsor
IRB / ETHICS COMMITTEE:
- Independent body ensuring protection of rights, safety, and well-being of subjects
- Must approve protocol before trial begins
- Conducts continuing review at least annually
- Has authority to suspend/terminate trial
ESSENTIAL DOCUMENTS:
- Investigator's Brochure (IB): Compilation of clinical & non-clinical data
- Case Report Form (CRF): Data collection instrument for each subject
- Informed Consent Form (ICF): Documented consent process
- Protocol: Detailed plan describing objectives, design, methodology
- Source Documents: Original records (hospital files, lab reports)
DATA INTEGRITY & AUDIT TRAIL:
- ALCOA+ principles: Attributable, Legible, Contemporaneous, Original, Accurate + Complete, Consistent, Enduring, Available
- Audit trail: Documentation that allows reconstruction of events
- Any change to data must be signed, dated, with reason
5. BIOSTATISTICS IN CLINICAL TRIALS (Calculation questions appear)
SAMPLE SIZE CALCULATION FACTORS:
- Significance level (α): Usually 0.05 (5%)
- Power (1-β): Usually 80% or 90%
- Effect size: Clinically meaningful difference
- Variability: Standard deviation of outcome measure
- Dropout rate: Usually 10-20% added
KEY STATISTICAL TESTS:
- t-test: Compare means between 2 groups
- ANOVA: Compare means between 3+ groups
- Chi-square test: Compare categorical variables
- Log-rank test: Compare survival curves
- Kaplan-Meier: Estimate survival probability over time
INTENTION-TO-TREAT (ITT) ANALYSIS:
- All randomized subjects analyzed in groups to which originally assigned
- Preserves randomization benefits
- Conservative estimate of treatment effect
PER-PROTOCOL (PP) ANALYSIS:
- Only subjects who completed protocol analyzed
- May overestimate treatment effect
- Used as sensitivity analysis alongside ITT
SURVIVAL ANALYSIS:
- Overall Survival (OS): Time from randomization to death from any cause
- Progression-Free Survival (PFS): Time until disease progression or death
- Hazard Ratio (HR): Relative risk of event in treatment vs control
- HR < 1: Favors treatment
- HR = 1: No difference
- HR > 1: Favors control
SECTION B: MEDICAL DEVICES - COMPLETE COVERAGE
1. MEDICAL DEVICES RULES, 2017 (HIGHEST PRIORITY | Directly tested in 2023)
DEFINITION (Section 3(b) of D&C Act, as amended):
"Medical device" means:
- Any instrument, apparatus, appliance, implant, material, or other article
- Used alone or in combination, including software/intended by manufacturer
- For diagnosis, prevention, monitoring, treatment, or alleviation of disease
- For diagnosis, monitoring, treatment, or alleviation of/compensation for injury
- For investigation, replacement, modification, or support of anatomy/physiological process
- For supporting or sustaining life
- For control of conception
- For disinfection of medical devices
- For providing information by in-vitro examination of specimens
- Does NOT achieve primary intended action by pharmacological, immunological, or metabolic means (but may be assisted by such means)
CLASSIFICATION OF MEDICAL DEVICES (Risk-based):
CLASS A - LOW RISK
- Examples: Tongue depressors, bandages, surgical gloves, stethoscopes, wheelchairs (non-powered), examination lamps
- Regulatory: Self-certification by manufacturer, Registration required
CLASS B - LOW-MODERATE RISK
- Examples: Hypodermic syringes, thermometers (digital), suction equipment, hearing aids, ultrasound scanners (non-invasive)
- Regulatory: Manufacturing license from State Licensing Authority (SLA)
- Import: Registration Certificate (RC) from CDSCO
CLASS C - MODERATE-HIGH RISK
- Examples: Orthopedic implants (bone plates, screws), ventilators, infusion pumps, dialysis equipment, X-ray machines, CT scanners, pregnancy test kits (IVD)
- Regulatory: Manufacturing license from Central Licensing Authority (CDSCO)
- Import: RC from CDSCO + Performance evaluation may be required
CLASS D - HIGH RISK
- Examples: Heart valves, coronary stents, pacemakers, implantable defibrillators, breast implants, HIV test kits (IVD), blood bags
- Regulatory: Manufacturing license from CDSCO (Central)
- Import: RC from CDSCO + MANDATORY clinical investigation/performance evaluation
PYQ TIP: Classification questions are VERY COMMON. Memorize examples!
"Which class is a coronary stent?" → Class D
"Which class is a thermometer?" → Class B
"Which class is a bandage?" → Class A
IN VITRO DIAGNOSTIC (IVD) DEVICES:
- Classified separately under same A/B/C/D system
- Examples:
- Class A: General lab equipment, specimen receptacles
- Class B: Blood glucose monitors, pregnancy test kits
- Class C: HIV test kits, blood grouping reagents
- Class D: Blood bags for transfusion, HIV blood donor screening
REGISTRATION PROCESS:
- SUGAM PORTAL: Online portal for medical device registration (cdsco.gov.in)
- Registration Certificate (RC): Required for import and manufacture
- Validity: 3 years (renewable)
- Notified Bodies: Accredited bodies for conformity assessment of Class A & B
MANUFACTURING LICENSES:
- Class A & B: State Licensing Authority (SLA)
- Class C & D: Central Licensing Authority (CDSCO)
- Requirements: Quality Management System (ISO 13485), technical documentation, risk management file, clinical evidence/performance evaluation
IMPORT OF MEDICAL DEVICES:
- Registration Certificate (RC) mandatory before import
- Import License required for each consignment
- Labeling requirements: MRP, manufacturing date, expiry date, batch/lot number, storage conditions, manufacturer's name & address, "Import License No."
PERFORMANCE EVALUATION / CLINICAL INVESTIGATION:
- Required for Class C & D devices (especially implantable)
- Types:
- Clinical Investigation: Prospective study in human subjects
- Clinical Performance Evaluation: Assessment of analytical/clinical performance
- Post-Market Clinical Follow-up (PMCF): Ongoing monitoring after approval
- Exemptions: If device has substantial equivalence to approved device
POST-MARKET SURVEILLANCE (PMS):
- Mandatory for all classes
- Requirements:
- Vigilance reporting: Serious incidents within specified timelines
- Periodic Safety Update Reports (PSUR)
- Post-market clinical follow-up studies (for high-risk devices)
- Manufacturer must maintain PMS system throughout device lifecycle
UNIQUE DEVICE IDENTIFICATION (UDI):
- Global system for device identification and traceability
- Components:
- Device Identifier (DI): Fixed portion identifying specific model
- Production Identifier (PI): Variable portion (batch, serial number, expiry)
- Barcode/RFID format
- Helps in: Recall management, adverse event reporting, supply chain tracking
2. COMPARISON: DRUGS vs MEDICAL DEVICES REGULATION
| PARAMETER | DRUGS | MEDICAL DEVICES |
|---|---|---|
| Governing Act | D&C Act 1940, Rules 1945 | D&C Act 1940, Medical Devices Rules 2017 |
| Regulator | CDSCO | CDSCO (Medical Device Division) |
| Approval | Marketing Authorization (MA) | Registration Certificate (RC) |
| Clinical Trials | Phases I-IV | Clinical Investigation (Performance Evaluation) |
| GMP Reference | Schedule M | ISO 13485, QMS requirements |
| Shelf Life | Schedule P | Determined by stability data |
| Labeling | Schedule H, H1, X, etc. | Specific labeling rules in Medical Devices Rules |
| Import | Import License + Registration | RC + Import License |
| Post-market | Pharmacovigilance (PvPI) | Medical Device Vigilance |
3. CDSCO STRUCTURE & MEDICAL DEVICE DIVISION
CDSCO (Central Drugs Standard Control Organisation):
- Headed by: Drugs Controller General of India (DCGI)
- Under: Directorate General of Health Services (DGHS), Ministry of Health & FW
- Headquarters: New Delhi (Kotla Road)
- Zonal Offices: Mumbai, Chennai, Kolkata, Ahmedabad, Hyderabad
MEDICAL DEVICE DIVISION:
- Separate division within CDSCO for medical device regulation
- Functions:
- Registration of medical devices
- Import license approval
- Clinical investigation approval
- Post-market surveillance coordination
- Adverse event monitoring
4. KEY AMENDMENTS & RECENT UPDATES (Current Affairs angle)
MEDICAL DEVICES RULES, 2017 - KEY FEATURES:
- Replaced earlier regulatory framework (drugs-based approach)
- Risk-based classification (A/B/C/D)
- SUGAM portal for online applications
- Provision for clinical investigation
- Post-market surveillance requirements
- UDI system provision
- Separate regulation for IVDs
IMPORTANT NOTIFICATIONS:
- All medical devices now regulated under D&C Act (expanded definition)
- Software as Medical Device (SaMD): AI/ML-based diagnostic tools regulated
- Telemedicine devices: Regulated under medical devices framework
- Neutraceuticals/Borderline products: Clarification on regulation
SECTION C: INTEGRATED TOPICS & CROSS-OVER CONTENT
1. SCHEDULE Y (Drugs & Cosmetics Rules, 1945) (Critical | Always tested with Clinical Trials)
Schedule Y covers: REQUIREMENTS AND GUIDELINES FOR PERMISSION TO IMPORT AND/OR MANUFACTURE NEW DRUGS FOR SALE OR TO UNDERTAKE CLINICAL TRIALS
KEY CONTENTS:
- Clinical trial requirements for new drugs
- Data required for new drug approval
- Format for clinical trial protocol
- Informed consent requirements
- Ethics committee requirements
- SAE reporting guidelines
- Post-marketing surveillance requirements
DATA REQUIREMENTS FOR NEW DRUG APPROVAL:
- Chemical and Pharmaceutical Information
- Animal Pharmacology
- Animal Toxicology
- Human/Clinical Pharmacology (Phase I)
- Therapeutic Confirmatory Trials (Phase III)
- Special studies (pediatric, geriatric, pregnancy)
- Published literature
- Regulatory status in other countries
2. COMPARISON: SCHEDULE Y vs ND&CT RULES 2019
| ASPECT | SCHEDULE Y (1945 Rules) | ND&CT RULES 2019 |
|---|---|---|
| Scope | Clinical trials + New drugs | Clinical trials + New drugs + Ethics committees + Compensation |
| Ethics Committee | Registration not mandatory | MANDATORY registration with DCGI |
| Compensation | Vague provisions | Clear formula + mandatory insurance/indemnity |
| Phase I Waiver | Not explicitly mentioned | Explicit provision for ICH country approved drugs |
| SAE Reporting | General guidelines | Specific timelines (7/15 days) |
| Informed Consent | Basic requirements | 11 essential elements specified |
| CTD Format | Not specified | Specified (ICH M4) |
IMPORTANT: Both are currently in force. ND&CT Rules 2019 is newer and more detailed. Questions may test differences between the two.
3. BIOSIMILARS & BIOLOGICS IN CLINICAL TRIALS
BIOSIMILAR DEFINITION:
- Biological product highly similar to reference product (originator)
- No clinically meaningful differences in safety, purity, potency
- NOT generic (generics = identical small molecules)
BIOSIMILAR APPROVAL REQUIREMENTS:
- Comparative analytical studies
- Non-clinical studies (in-vitro, in-vivo)
- Clinical studies: PK/PD comparability + confirmatory efficacy/safety
- Immunogenicity assessment (mandatory)
- Extrapolation: May be approved for indications not directly studied
PYQ TIP: "Can biosimilar be approved without Phase III?" → NO, requires confirmatory clinical study (though may be abbreviated vs originator)
SECTION D: PYQ PATTERN ANALYSIS & EXAM STRATEGY
1. QUESTION TYPES OBSERVED (2015-2023)
TYPE A: DEFINITION-BASED
- "What is the minimum number of subjects in Phase II clinical trial?"
Answer: 100-300 - "Define Serious Adverse Event (SAE)"
Answer: Event that results in death, life-threatening, hospitalization, disability/incapacity, congenital anomaly, or other medically important event
TYPE B: REGULATORY PROCEDURE
- "Timeline for reporting fatal SAE to DCGI?"
Answer: 7 days - "Which authority issues manufacturing license for Class C medical device?"
Answer: Central Licensing Authority (CDSCO)
TYPE C: CLASSIFICATION
- "Classify the following medical device: Coronary stent"
Answer: Class D (High risk) - "Pregnancy test kit belongs to which class of IVD?"
Answer: Class B (Low-moderate risk)
TYPE D: SCENARIO-BASED (Most Difficult)
- "A pharma company wants to conduct clinical trial of a drug already approved in USA. Which phase can be waived?"
Answer: Phase I (if approved in ICH country) - "During Phase III trial, a subject dies. What is the reporting timeline?"
Answer: 7 days to EC and DCGI
TYPE E: COMPARISON
- "Difference between bioavailability and bioequivalence"
Answer: Bioavailability = rate & extent of active ingredient reaching systemic circulation. Bioequivalence = comparison of bioavailability between two formulations of same drug.
2. HIGH-YIELD FACTS FOR QUICK REVISION
- CLINICAL TRIALS:
– Phase I: 20-100 subjects, healthy volunteers, safety/PK
– Phase II: 100-300 subjects, patients, efficacy/dose-finding
– Phase III: 1000-3000+ subjects, RCT, confirmatory
– Phase IV: Post-marketing, pharmacovigilance, rare ADRs
– SAE reporting: Fatal = 7 days; Other serious = 15 days
– Ethics Committee: Must be registered with DCGI
– Informed Consent: 11 essential elements
– Phase I waiver: Possible for ICH-country approved drugs
– CTD format: ICH M4 (5 modules)
– Compensation: Mandatory for trial-related injury/death - MEDICAL DEVICES:
– Class A: Low risk (bandage, tongue depressor)
– Class B: Low-moderate risk (syringe, thermometer)
– Class C: Moderate-high risk (orthopedic implant, ventilator)
– Class D: High risk (heart valve, coronary stent, pacemaker)
– SUGAM portal: Online registration system
– RC validity: 3 years
– Class A/B license: State Licensing Authority
– Class C/D license: Central Licensing Authority (CDSCO)
– UDI: Device Identifier + Production Identifier
– Post-market surveillance: Mandatory for all classes
3. COMMON CONFUSIONS TO AVOID
- CONFUSION 1: "All clinical trials require Phase I"
CORRECTION: Phase I can be waived for drugs approved in ICH countries - CONFUSION 2: "Ethics Committee approval is optional for Phase IV"
CORRECTION: ALL phases require EC approval. Phase IV may have abbreviated review but EC approval is mandatory. - CONFUSION 3: "Medical devices don't need clinical trials"
CORRECTION: Class C & D devices require clinical investigation/performance evaluation. Only Class A & B may be exempted based on predicate device. - CONFUSION 4: "Bioequivalence means same as bioavailability"
CORRECTION: Bioavailability is absolute; bioequivalence is comparative between two products. - CONFUSION 5: "SAE and ADR are the same"
CORRECTION: SAE = Serious Adverse EVENT (any serious untoward occurrence) ADR = Adverse DRUG Reaction (causally related to drug). All ADRs are events but not all events are drug reactions.
SECTION E: QUICK REFERENCE TABLES
TABLE 1: CLINICAL TRIAL PHASES AT A GLANCE
| Phase | Subjects | Type | Primary Objective |
|---|---|---|---|
| Phase 0 | 10-15 | Healthy/Patients | Microdosing, PK exploratory |
| Phase I | 20-100 | Healthy | Safety, tolerability, PK |
| Phase II | 100-300 | Patients | Efficacy, dose-finding |
| Phase III | 1000-3000+ | Patients | Confirmatory efficacy |
| Phase IV | Unlimited | General public | Post-marketing safety |
TABLE 2: MEDICAL DEVICE CLASSIFICATION WITH EXAMPLES
| Class | Risk Level | Examples |
|---|---|---|
| A | Low | Bandage, tongue depressor, surgical gloves, stethoscope, wheelchair (manual) |
| B | Low-Moderate | Syringe, thermometer, suction equipment, hearing aid, ultrasound (diagnostic) |
| C | Moderate-High | Orthopedic implant, ventilator, infusion pump, dialysis machine, CT scanner, X-ray |
| D | High | Heart valve, coronary stent, pacemaker, breast implant, HIV test kit, blood bag |
TABLE 3: SAE REPORTING TIMELINES
| SAE Type | Timeline | Report To |
|---|---|---|
| Fatal / Life-threatening | Within 7 days | Ethics Committee + DCGI |
| Other Serious SAE | Within 15 days | Ethics Committee + DCGI |
| SUSAR (Unexpected) | Same as above | Ethics Committee + DCGI |
| Follow-up information | As available | Same authorities |
TABLE 4: ETHICS COMMITTEE COMPOSITION
| Member Category | Requirement |
|---|---|
| Chairperson | Independent, not from institution |
| Medical/Scientific Members | 1-2 basic scientists + 1-2 clinicians |
| Legal Expert | 1 |
| Social Scientist/NGO Rep | 1 |
| Philosopher/Ethicist/Theologian | 1 |
| Lay Person | 1 from community |
| Member Secretary | 1 |
| Independent Member | At least 1 not affiliated |
| Quorum | Min 5 including Chair + 1 clinician |
TABLE 5: KEY REGULATORY AUTHORITIES & PORTALS
| Authority/Portal | Purpose |
|---|---|
| CDSCO | Central drug & medical device regulation |
| DCGI | Drugs Controller General of India (Head) |
| SUGAM Portal | Online medical device registration |
| SLA | State Licensing Authority (Class A/B devices) |
| Notified Bodies | Conformity assessment (Class A/B) |
| Ethics Committee | Protocol review, subject protection |
| ICMR | Clinical trial guidelines, bioethics |
SECTION F: PRACTICE QUESTIONS (PYQ-Style)
Q1. A drug approved in the USA is being introduced in India for clinical trials.
Which phase can be waived as per ND&CT Rules 2019?
(a) Phase I only (b) Phase II only (c) Phase I & II (d) None
Answer: (a) Phase I only (if approved in ICH country)
Q2. The SUGAM portal is used for:
(a) Drug manufacturing license
(b) Medical device registration
(c) Pharmacist registration
(d) Clinical trial Ethics Committee approval
Answer: (b) Medical device registration
Q3. A coronary stent is classified as:
(a) Class A (b) Class B (c) Class C (d) Class D
Answer: (d) Class D
Q4. Timeline for reporting a fatal Serious Adverse Event to DCGI is:
(a) 24 hours (b) 7 days (c) 15 days (d) 30 days
Answer: (b) 7 days
Q5. Which of the following is NOT an essential element of informed consent?
(a) Expected duration of participation
(b) Financial compensation for participation
(c) Description of foreseeable risks
(d) Statement that participation is voluntary
Answer: (b) Financial compensation for participation (not mandatory element)
Q6. Double-blind clinical trial means:
(a) Neither patient nor investigator knows treatment assignment
(b) Only patient is blinded
(c) Only investigator is blinded
(d) Data analyst is blinded
Answer: (a) Neither patient nor investigator knows treatment assignment
Q7. Manufacturing license for Class C medical device is issued by:
(a) State Licensing Authority
(b) Central Licensing Authority (CDSCO)
(c) District Licensing Authority
(d) Notified Body
Answer: (b) Central Licensing Authority (CDSCO)
Q8. The minimum number of subjects typically required for Phase III trial is:
(a) 20-100 (b) 100-300 (c) 500-1000 (d) 1000-3000+
Answer: (d) 1000-3000+
Q9. CONSORT guidelines are used for:
(a) Good Manufacturing Practice
(b) Reporting of randomized controlled trials
(c) Medical device classification
(d) Pharmacovigilance
Answer: (b) Reporting of randomized controlled trials
Q10. Compensation for clinical trial-related injury is:
(a) Optional, depends on sponsor
(b) Mandatory as per ND&CT Rules 2019
(c) Only for death, not injury
(d) Decided by Ethics Committee case by case
Answer: (b) Mandatory as per ND&CT Rules 2019
SECTION G: INTERVIEW-READY TALKING POINTS
If asked about Clinical Trials & Medical Devices in the UPSC Interview:
- CURRENT STATUS OF INDIA:
"India is emerging as a global hub for clinical trials due to diverse genetic pool, large patient population, and cost advantages. However, we need to balance this with robust ethical oversight." - ND&CT RULES 2019 IMPACT:
"The 2019 rules brought India at par with ICH-GCP standards. Key improvements: mandatory EC registration, clear compensation formula, Phase I waiver for ICH-approved drugs, and specific SAE timelines." - MEDICAL DEVICES SECTOR:
"India imports ~80% of medical devices. The 2017 Rules created a risk-based regulatory framework. Recent expansion of regulated device categories shows government's commitment to patient safety." - CHALLENGES:
"Challenges include: limited EC capacity in tier-2/3 cities, post-market surveillance infrastructure, and balancing innovation with safety for emerging technologies like AI-based devices." - YOUR ROLE AS DRUG INSPECTOR:
"As Drug Inspector, I would ensure compliance with ND&CT Rules during GCP inspections, verify SAE reporting, and monitor medical device adverse events in my jurisdiction."
SECTION H: ONE-PAGE FINAL REVISION SHEET
| CLINICAL TRIALS & MEDICAL DEVICES FINAL RAPID REVISION | |
|---|---|
| PHASES: | I(20-100, healthy, safety) → II(100-300, patients, efficacy) → III(1000-3000+, RCT, confirmatory) → IV(post-marketing) |
| ND&CT RULES 2019: | Phase I waiver (ICH countries) | EC registration mandatory SAE: Fatal=7 days | Other=15 days | Compensation mandatory ICF: 11 essential elements | CTD: ICH M4 format (5 modules) |
| GCP (ICH E6): | Ethics | Scientific quality | Risk-benefit | Informed consent | Confidentiality |
| DEVICES: | A(low)←B(low-mod)←C(mod-high)←D(high) A: Bandage, glove | B: Syringe, thermometer | C: Implant, ventilator D: Stent, valve, pacemaker | SUGAM portal | RC=3 years A/B: State license | C/D: Central (CDSCO) license UDI: Device Identifier + Production Identifier Post-market surveillance: Mandatory for all classes |
| SCHEDULE Y: | Clinical trial requirements | Data for NDA | EC guidelines |
| COMPARE: | Schedule Y (1945) vs ND&CT Rules 2019 - know 5 key differences |
| BIOSIMILARS: | Highly similar to reference | Requires comparative clinical data | Immunogenicity assessment mandatory |
Prepared for: UPSC Drug Inspector 2026 Examination
Subject: Clinical Trials & Medical Devices (Rising Minor Subject)
Sources: UPSC DI Syllabus 2012+2023, ND&CT Rules 2019, Medical Devices Rules 2017, PYQ Analysis 2015-2023, ICH E6(R2) GCP Guidelines
Study Strategy for this subject:
- Day 1-2: Read complete file, highlight weak areas
- Day 3: Memorize classification tables and timelines
- Day 4: Solve all practice questions + 50 additional MCQs
- Day 5: Revision + create own 1-page cheat sheet
- Day 6: Mock test (25 questions, 25 minutes)
- Day 7: Error analysis + re-read confusing topics
Estimated study time: 40-45 hours for mastery
Expected marks if mastered: 10-15 out of 300 (rising to 15-20 by 2026)
Upgrade to Success Pass (₹30) to unlock downloads and printing.